Di Battista M, Marcucci E, Elefante E, Tripoli A, Governato G, Zucchi D, et al. One year in review 2018: systemic lupus erythematosus. Clin Exp Rheumatol. 2018;36:763–77. http://www.ncbi.nlm.nih.gov/pubmed/30272543.
Malaviya AN, Singh RR, Singh YN, Kapoor SK, Kumar A. Prevalence of systemic lupus erythematosus in India. Lupus. 1993;2(2):115–8. http://www.ncbi.nlm.nih.gov/pubmed/8330032.
Kumar Y, Bhatia A, Minz RW. Antinuclear antibodies and their detection methods in diagnosis of connective tissue diseases: a journey revisited. Diagn Pathol. 2009;4:1. http://www.ncbi.nlm.nih.gov/pubmed/19121207.
Dalle Vedove C, Simon JC, Girolomoni G. Drug-induced lupus erythematosus with emphasis on skin manifestations and the role of anti-TNFα agents. J Dtsch Dermatol Ges. 2012;10:889–97. http://www.ncbi.nlm.nih.gov/pubmed/22937775.
Solhjoo M, Ho CH, Chauhan K, Gossman W. Drug-induced lupus erythematosus. StatPearls. Treasure Island: StatPearls Publishing; 2019. http://www.ncbi.nlm.nih.gov/pubmed/28722919.
Uppsala Monitoring Center. Why causality assessment? In: The use of the WHO-UMC system for standardised case causality assessment. https://www.who.int/medicines/areas/quality_safety/safety_efficacy/WHOcausality_assessment.pdf. Accessed 19 Feb 2019.
Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239–45. http://doi.wiley.com/10.1038/clpt.1981.154.
Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm. 1992;49:2229–32. http://www.ncbi.nlm.nih.gov/pubmed/1524068.
Janeway CA Jr, Travers P, Walport M, Shlomchik MJ. Autoimmune responses are directed against self antigens. In: Immunobiology: the immune system in health and disease. 5th ed. New York: Garland Science; 2001. https://www.ncbi.nlm.nih.gov/books/NBK27155/.
Poole BD, Scofield RH, Harley JB, James JA. Epstein–Barr virus and molecular mimicry in systemic lupus erythematosus. Autoimmunity. 2006;39:63–70. http://www.ncbi.nlm.nih.gov/pubmed/16455583.
Tetikkurt C. Drug-induced lupus syndrome. J Vasc. 2016;2(3). https://www.omicsonline.org/open-access/druginduced-lupus-syndrome-2471-9544-100115.php?aid=80257.
Sim E, Laurieri N. Isoniazid induced toxicity: systemic lupus erythematosus. J Drug Des Res. 2018;5(1):1065. https://www.jscimedcentral.com/DrugDesign/drugdesign-5-1065.pdf.
Rakotoson JL, Randriamanana D, Rakotomizao JR, Andrianasolo R, Rakotoarivelo R, Andrianarisoa ACF. Lupus érythémateux systémique grave induit par l’isoniazide. Rev Pneumol Clin. 2009;65:361–4. https://linkinghub.elsevier.com/retrieve/pii/S0761841709001394.
Jguirim M, Jbeli A, Brahim H Ben, Mhenni A, Youssef M, Touzi M, et al. Lupus érythémateux systémique induit par l’isoniazide: une complication rare à craindre. Pan Afr Med J. 2015;20:181. http://www.ncbi.nlm.nih.gov/pubmed/26430478.